In vivo verification of tumor suppressors and their interactions with each other has required complex experiments. A report in this issue uses a novel CRISPR–Cas9 technology with barcodes to test, in parallel, the tumorigenic potential of functional loss of multiple tumor-suppressor genes in the context of a genetically engineered mouse model of lung adenocarcinoma with mutant Kras.
References
Cancer Genome Atlas Research Network. Nature 489, 519–525 (2012).
Cancer Genome Atlas Research Network. Nature 511, 543–550 (2014).
Ettinger, D. S. et al. J. Natl. Compr. Canc. Netw. 15, 504–535 (2017).
George, J. et al. Nature 524, 47–53 (2015).
Steuer, C. E. & Ramalingam, S. S. J. Clin. Oncol. 36, 631–632 (2018).
Zehir, A. et al. Nat. Med. 23, 703–713 (2017).
Rogers, Z. N. et al. Nat. Genet. https://doi.org/10.1038/s41588-018-0083-2 (2018).
Rogers, Z. N. et al. Nat. Methods 14, 737–742 (2017).
Sánchez-Rivera, F. J. et al. Nature 516, 428–431 (2014).
Walter, D. M. et al. Cancer Res. 77, 1719–1729 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kim, J., Minna, J.D. Evaluating tumor-suppressor gene combinations. Nat Genet 50, 480–482 (2018). https://doi.org/10.1038/s41588-018-0095-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-018-0095-y
- Springer Nature America, Inc.